Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilize extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.
Abstract: An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.
Type:
Grant
Filed:
April 11, 2002
Date of Patent:
December 28, 2010
Assignee:
Galephar Pharmaceutical Research, Inc.
Inventors:
Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
Abstract: A composition having effective broad spectrum preservation activity comprising a mixture of caprylyl glycol or one or more analogs thereof, or mixtures thereof with a preservative selected from the group consisting of: (1) chloroxylenol and 2-phenoxyethanol, (2) chloroxylenol and chlorphenesin, (3) chlorphenesin and 2-phenoxyethanol, and (4) chloroxylenol, chlorphenesin and 2-phenoxyethanol.
Type:
Grant
Filed:
September 12, 2005
Date of Patent:
December 21, 2010
Assignee:
Arch Chemicals, Inc.
Inventors:
Diana T. Ciccognani, Kevin N. DiNicola, Stephen D. Hinden, Katherine P. Roberts
Abstract: The present invention relates to dehydrated Type II collagen containing cartilage which has retained the collagen in its original crosslinked structure and which contains at least 40% by weight of the Type II collagen of an ionizable edible salt and which has a water content of less than 10%.
Abstract: Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.
Abstract: A bisphosphonic acid derivative-containing percutaneous preparation of an excellent percutaneous permeability, comprising a bisphosphonic acid derivative such as incadronic acid, minodronic acid, etc., or pharmaceutically acceptable salts thereof, a solubilizing agent for the derivative or pharmaceutically acceptable salts thereof, and an amphiphilic solubilizing auxiliary agent, which may optionally contain a suspension-type base such as a polyvalent alcohol, a higher fatty acid ester, a liquid hydrocarbon or a vegetable oil, etc. This preparation has an excellent percutaneous permeability, reduces burdens on the patient, does not deteriorate the patient's compliance even in the administration over a prolonged period of time and can achieve the therapeutic effects in a short period of time.
Abstract: The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard gelatin capsules.
Abstract: A novel ?-lipoic acid derivative represented by the following formula (I). It has a tyrosinase inhibiting activity, melanin production inhibitory activity, and elastase inhibiting activity. (I) (In the formula, M represents a metal and A denotes an amino acid residue bonded through the nitrogen atom.).
Type:
Grant
Filed:
March 18, 2002
Date of Patent:
April 20, 2010
Assignee:
Senju Pharmaceutical Co., Ltd.
Inventors:
Kazumi Ogata, Takahiro Sakaue, Kazuhiko Ito
Abstract: The invention pertains to a method of treating or preventing pressure ulcers, comprising enterally administering to a subject in need thereof a composition comprising proteins, carbohydrates, fats, arginine or equivalents thereof, ascorbic acid equivalents and ?-tocopherol equivalents, wherein arginine or equivalents thereof is administered in a daily amount of 3-15 g, ascorbic acid equivalents are administered in a daily amount of 180-840 mg and ?-tocopherol equivalents are administered in a daily amount of 50-400 mg.
Type:
Grant
Filed:
November 22, 2004
Date of Patent:
April 13, 2010
Assignee:
N.V. Nutricia
Inventors:
Maria Anna Verheul-Koot, Chantal Nelleke Kleijer, Robert Johan Joseph Hageman, Roelof Andre Bork, Maud Goethals
Abstract: Water-soluble compositions comprising a lipophilic compound and a solubilizing agent of the general formula: {X—OOC—[(CH2)n—COO]m}p—Y??(I) wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol or sitosterol, the tocopherol is ?-(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is equal to 1 or 2, m is equal to 0 or 1 and n is an integer between 2 and 18.
Type:
Grant
Filed:
August 27, 2003
Date of Patent:
January 12, 2010
Assignee:
National Research Council of Canada
Inventors:
Henryk Borowy-Borowski, Marianna Sikorska-Walker, P. Roy Walker
Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
Type:
Grant
Filed:
October 5, 2004
Date of Patent:
November 10, 2009
Assignee:
Graceway Pharmaceuticals, LLC
Inventors:
Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
Abstract: Surgical osteosynthesis composite material which has three components: biodegradable polymer reinforcement, bioceramic or bioglass filler reinforcement and biodegradable polymer matrix. This invention relates to biodegradable materials used for bone fracture fixation devices and methods of their manufacture. Unlike other known materials used prior to this application, the composites of this invention have two different reinforcing phases and one matrix phase. One reinforcing element is referred as the polymeric reinforcing element and the other as the ceramic reinforcing element.
Type:
Grant
Filed:
September 2, 1997
Date of Patent:
June 2, 2009
Assignee:
Linvatec Biomaterials Oy
Inventors:
Pertti Törmälä, Minna Kellomäki, William Bonfield, Kathleen Elizabeth Tanner
Abstract: The present invention relates to novel, topically applied, cosmetic/dermatological compositions for the treatment of hyperpigmentation disorders and photodamaged human skin. The subject compositions combat hyperpigmented skin. In addition, the compounds described can be used in the treatment of many other pathologies. Due to a high degree of gentleness, along with potent antioxidant and moisturizing effects, the present invention can be used safely in the treatment of many conditions, such as the prevention and/or treatment of melasma, freckles, age spots (lentigo senilis) and photodamaged skin.
Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.
Abstract: A two-stage treatment process suitable for the permanent deformation and/or shaping of keratinous substances and, in particular, the hair includes the application of a reducing composition containing, in addition to a reducing agent, an organic absorbing agent followed, after an optional rinsing, by the application of a neutralizing composition and by the rinsing of the keratinous substances thus treated.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
February 10, 2009
Assignee:
L'Oreal
Inventors:
Ly-Lan Nguyen, Anne Sabbagh, Priscilla Devin-Baudoin
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed.
Type:
Grant
Filed:
July 7, 2003
Date of Patent:
July 15, 2008
Assignee:
Collegium Pharmaceutical, Inc.
Inventors:
Jane Hirsh, Alexander M. Kibanov, Timothy M. Swager, Stephen L. Buchwald, Whe Yong Lo, Alison B. Fleming, Roman V. Rariy
Abstract: The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more additional active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release.
Type:
Grant
Filed:
February 11, 2002
Date of Patent:
May 20, 2008
Assignee:
Lipocine, Inc.
Inventors:
Feng-Jing Chen, Srinivasan Venkateshwaran, Steven L. Krill, Mahesh V. Patel
Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.
Abstract: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.